Improving hydroxyurea use for sickle cell disease in Nigeria
Official title: mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria
Run by New York University · NCT06318143 · Data updated 2026-11-12
This study is testing a special training program for healthcare workers in Nigeria to see if it can help more people with sickle cell disease start using hydroxyurea treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 12 Months and up |
| Sex | All |
| Enrollment | 900 (estimated) |
| Sponsor | New York University Academic / other |
| Locations | 1 site (Abuja) |
| Status | Recruiting |
| Started | July 1, 2024 |
| Main results expected | June 30, 2027 |
| Study ends | May 31, 2028 |
| Registry record updated | July 7, 2026 |
| Trial ID | NCT06318143 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include SCD patients aged 9 months and older who are not currently on hydroxyurea therapy and have provided informed consent.
✕Probably not a fit
Patients who are already receiving hydroxyurea therapy or are not registered in the electronic medical records database will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the adoption of hydroxyurea (HU) therapy among sickle cell disease (SCD) patients in Nigeria, where current usage is less than 1%. It will utilize a cluster randomized controlled trial (RCT) to compare the effectiveness of a tailored training program for healthcare workers against standard educational information in promoting HU adoption. The study will also assess factors influencing the implementation and sustainability of this intervention across 20 clinical sites. By leveraging existing healthcare infrastructure, the research seeks to identify best practices for improving SCD management in resource-limited settings.
Why it matters
Potential benefit: If successful, this study could significantly increase the adoption of hydroxyurea therapy, leading to improved health outcomes and reduced mortality for sickle cell disease patients in Nigeria.
How similar studies have gone: Other studies have shown success in improving treatment adoption through tailored interventions, suggesting potential for this approach in similar contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * SCD patients18 years older that have provided consent; * Pediatric SCD patients aged 12 months to 17 years with an accompanying guardian and have provided informed consent or assent; * Registration in the electronic medical records (EMR) database with clinical charts and received care at the local clinical sites or health facilities and not on HU therapy; * Hb Genotype: SCD-SS, SCD-Sβo thal, SCD-SOArab (On a case by case basis, a severely affected person with SCD-SC may be offered HU therapy under a modified treatment protocol) Exclusion Criteria: * Any SCD patient not registered in the EMR database without informed consent or assent; * Physically unable to participate in study activities; * An SCD patient on HU
Where it's running
-
University Of Abuja Teaching Hospital
Abuja, Nigeria Recruiting
Study contacts
- Study coordinator: Emmanuel Peprah, PhD
- Email: ep91@nyu.edu
- Phone: 212-992-6085
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients
This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Newborn Sickle Cell Screening in Mozambique
We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.
-
Optimizing Hydroxyurea in Children with Sickle Cell in Africa
This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.
-
Hematopoietic stem cell editing to treat sickle cell disease
This study tests whether a patient’s own blood stem cells can be edited to remove the sickle cell triggering gene and then returned to the patient.
-
Virtual reality options to help with VOC pain in adults with SCD
This study tests whether headset-based virtual reality can help reduce pain for adults with sickle cell disease during vaso-occlusive crises treated in an infusion center.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.